ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1575

CD6 Is a Target for Cancer Immunotherapy

Jeffrey Ruth1, Mikel Gurrea Rubio2, Kalana Athukorala3, Stephanie Rasmussen1, Weber Daniel1, Peggy Randon1, M Asif Amin1, Phillip Campbell1, Pei-suen Tsou1, Yang Mao-Draayer1, Qi Wu4, Matthew Lind1, Rosemary Gedert1, Thomas Lanigan1, Venkateshwar Keshamouni1, Nora Singer5, Feng Lin6 and David Fox7, 1University of Michigan, Ann Arbor, MI, 2Division of Rheumatology, University of Michigan, Canton, MI, 3University of Michigan, Ann Arbor, MN, 4University of Michigan, Ann Arbor, 5The MetroHealth System, Case Western Reserve University School of Medicine, Cleveland, OH, 6Cleveland Clinic Foundation, Cleveland, OH, 7Division of Rheumatology, University of Michigan, Ann Arbor, MI

Meeting: ACR Convergence 2020

Keywords: Biologicals, Cytotoxic Cells, immunology, Mouse Models, Other, Natural Killer Cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Immunological Complications of Therapy Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Limitations of checkpoint inhibitor immunotherapy include induction of autoimmune syndromes and resistance of many cancers. Definition of additional molecular targets is required. CD6, expressed by most human T lymphocytes and a subset of natural killer (NK) cells, engages the ligands CD166/ALCAM and CD318. Interrupting CD6 interaction with its ligands prevents or reverses mouse models of rheumatoid arthritis, multiple sclerosis and uveitis, due to suppression by UMCD6 of differentiation of effector Th1 and Th17 cells. As CD6 ligands are broadly expressed on cancer cells and high expression of CD318 is associated with aggressive and metastatic cancer, we hypothesized that interruption of CD6/CD6 ligand interactions would enhance lymphocyte killing of cancer cells.

Methods: Flow cytometry was used to define expression of CD6 ligands on human breast, lung and prostate cancer cell lines. Soluble CD318 was measured by ELISA. To develop cell lines with nuclear red fluorescence for live imaging, cancer cells were transfected with an mKate2 2X nuclear localization fusion construct. Co-cultures of cancer cells with peripheral blood mononuclear cells (PBMC) or purified CD4+, CD8+ and NK cells were imaged in an IncuCyte® S3 Live Cell Analysis System every 30-60 minutes for 5 to 7 days. A caspase-sensitive green fluorescent dye detected dying cancer cells.  To monitor tumor growth by bioluminescent imaging in vivo, MDA-MB-231 breast cancer cells were transduced with a luciferase lentivirus reporter. SCID/beige mice  were injected sc with 5×106 luciferase-transfected breast cancer cells. Tumors were imaged by bioluminescence and at day 26 mice received 1.2×107 PBMCs iv. The next day mice received a single dose of UMCD6 or an IgG control antibody (400µg/mouse ip). Tumor growth was measured by bioluminescence, using a Xenogen IVIS 200 instrument.  Tumors were removed at day 36 and examined by fluorescent immunohistology.

Results: Most human cancer cell lines were strongly positive for both CD318 and CD166. CD318+ lines shed soluble CD318 at concentrations that were chemotactic for CD6+ lymphocytes. UMCD6 strikingly augmented killing of breast, lung or prostate cancer cells in co-cultures with human lymphocytes, through direct effects on both CD8+ T cells and NK cells, increasing cancer cell death and lowering cancer cell survival more robustly than checkpoint inhibitors that interrupt PD-1/PD-L1. UMCD6 also augmented in vivo killing by PBMC of a human breast cancer line xeno-transplanted into immunodeficient mice. A single injection of 0.4 mg per mouse one day after infusion of PBMC led to near disappearance of tumors in mice that received UMCD6 but not control IgG.  Histology showed extensive infiltration and activation of T lymphocytes and NK cells, with the NK cells over-represented in the tumor-infiltrating lymphocytes

Conclusion: The combined capabilities of UMCD6 to control autoimmunity through effects on CD4+ lymphocyte differentiation, while enhancing killing of cancer cells through distinct effects on CD8+ and NK cells, open a potential new approach to cancer immunotherapy that would suppress rather than instigate autoimmunity.

The anti-CD6 monoclonal antibody UMCD6 induces lymphocytes to kill cancer cells.

UMCD6 directly activates cytotoxic lymphocytes and is more potent than conventional checkpoint inhibitors.

UMCD6 induces lymphocyte-mediated cancer regression in vivo.


Disclosure: J. Ruth, None; M. Gurrea Rubio, None; K. Athukorala, None; S. Rasmussen, None; W. Daniel, None; P. Randon, None; M. Amin, None; P. Campbell, None; P. Tsou, None; Y. Mao-Draayer, None; Q. Wu, None; M. Lind, None; R. Gedert, None; T. Lanigan, None; V. Keshamouni, None; N. Singer, None; F. Lin, Takeda, 5; D. Fox, None.

To cite this abstract in AMA style:

Ruth J, Gurrea Rubio M, Athukorala K, Rasmussen S, Daniel W, Randon P, Amin M, Campbell P, Tsou P, Mao-Draayer Y, Wu Q, Lind M, Gedert R, Lanigan T, Keshamouni V, Singer N, Lin F, Fox D. CD6 Is a Target for Cancer Immunotherapy [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/cd6-is-a-target-for-cancer-immunotherapy/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cd6-is-a-target-for-cancer-immunotherapy/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology